Insider buying last 90 days
No open-market insider purchases were filed for INCY in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Incyte raised its full-year 2026 sales guidance to a range of $5,210 million to $5,300 million after third-quarter revenue rose 14% to $1.56 billion, with growth in dermatology and oncology reducing reliance on Jakafi. The company also reported a net loss of $784.8 million for the quarter alongside the guidance increase. Separately, Incyte is advancing two experimental cancer treatments, INCB161734 and INCA33890, into late-stage trials for pancreatic and colorectal cancers, following encouraging early-stage data presented at the 2026 ESMO Congress. H.C. Wainwright maintained a Buy rating on the stock with a $152.00 price target.
Shares closed at $121.89, up 1.9%, sitting above both the 50-day average of $119.57 and the 200-day average of $108.53, with the 50-day above the 200-day. The GekkoIndex reads 51.8, placing the stock in the Neutral zone. Price sits within 0.2% of Gekko Fair Value, which stands at $122.09.
The next earnings report is scheduled for 9 February 2027, 86 days away, placing it outside a typical 20-trading-day holding window. Over the last 90 days, Congress recorded 1 buy and 0 sells. Seasonality from this point in the calendar shows the next 20 trading days averaging -1.2% over 5 years, with gains in 3 of those years. Analyst consensus across 21 firms stands at 10 buy and 11 hold ratings, with a consensus target of $130.92.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Incyte scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive2 mixed0 headwinds
Above 50 and 200-day
Close $120.97 is above the 50-day ($119.18) and 200-day ($108.92) averages, and the 50-day is above the 200-day.
See the chart53.8, Neutral
Reading 53.8 is in the Neutral zone.
See the GekkoIndex1.7% above
Price is within 5% of Gekko Fair Value (1.7% above).
See fair valueLeans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart moneyReports in 86 days
Next report Feb 9, 2027, 86 days away — outside a typical 20-trading-day hold.
See earnings+2.6% on average
From this point in the calendar, the next 20 trading days averaged +2.6% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Incyte closed at $120.97 on Nov 13, 2026, +11.7% over the past year, inside a 52-week range of $89.25 to $132.60.
Use the left and right arrow keys to read daily values.
Put INCY on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Incyte develops and sells medicines it discovers and researches itself, focusing on treatments for cancers and blood disorders. Its marketed products include Jakafi, used for myelofibrosis and polycythemia vera, Pemazyre, aimed at cancers driven by a specific enzyme abnormality, and Iclusig, prescribed for certain forms of leukemia. These approved therapies form the core of what the company is recognized for in the market today.
Beyond its current drugs, Incyte runs a pipeline of experimental treatments in various stages of clinical testing, covering conditions such as graft-versus-host disease, bladder cancer, lymphoma, endometrial cancer, and lung cancer, among others. The company works with a range of outside partners, including Novartis, Eli Lilly, and Agenus, and participates in joint clinical studies with firms such as MorphoSys and Xencor to test combination treatments for lymphoma patients. Its business relies on advancing both marketed drugs and this broader research pipeline through internal work and collaboration.
Incyte was founded in 1991 and is headquartered in Wilmington, Delaware. Its shares are listed on the NASDAQ under the ticker INCY.
Incyte’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.8, in the Neutral zone, up 0.3 points over five sessions.
Up 0.3 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 47 | +0.2% | +3.2% | ||
| Accumulation | 176 | +1.1% | +0.8% | ||
| Neutral (current zone) | 419 | +0.5% | +3.2% | ||
| Distribution | 53 | 0.0% | 0.0% | ||
| Selling | 7 | Too few readings yet | |||
Average INCY share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Incyte trades 1.7% above Gekko Fair Value of $118.98, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Incyte shares are worth, recalculated every trading day.
$118.98
Gekko Fair Value, Nov 14, 2026
1.7% above fair value · About fair value
At the end of Aug 2026 the price was 1.1% above the estimate.
No open-market insider purchases were filed for Incyte, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for INCY in the last 90 days.
From Form 4 filings, dated to when each was filed.
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 4 |
From congressional disclosures, which report amounts as ranges.
Incyte has been buying back its own shares.
From company filings.
Incyte reports on Feb 9, 2027, before the open (86 days away), and beat the EPS estimate in 5 of its last 8 reports.
Feb 9, 2027
Expected before the open, 86 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 28, 2026 | $2.80 est $1.76 | $1.67B est $1.50B | +6.9% |
| Apr 28, 2026 | $1.81 est $1.34 | $1.27B est $1.22B | +3.5% |
| Feb 10, 2026 | $1.80 est $1.90 | $1.51B est $1.35B | −9.3% |
| Oct 28, 2025 | $2.26 est $1.66 | $1.37B est $1.35B | −3.1% |
| Jul 29, 2025 | $1.57 est $1.39 | $1.22B est $1.26B | +10.5% |
| Apr 29, 2025 | $1.16 est $1.01 | $1.05B est $1.15B | +5.3% |
| Feb 10, 2025 | $1.43 est $1.55 | $1.18B est $1.00B | −10.5% |
| Oct 29, 2024 | $0.54 est $0.79 | $1.14B est $1.14B | +12.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Incyte is $131.50, +8.7% from the last close, from 21 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 21 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 5 | Leerink Partners | $150 | +24.0% |
| Nov 5 | Canaccord Genuity | $152 | +25.7% |
| Nov 5 | H.C. Wainwright | $152 | +25.7% |
| Nov 2 | H.C. Wainwright | $152 | +25.7% |
| Nov 2 | Bank of America Securities | $143 | +18.2% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Incyte averaged +2.6% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −3.5% | 1 of 5 |
| Next 10 trading days | −1.1% | 2 of 5 |
| Next 15 trading days | −0.6% | 3 of 5 |
| Next 20 trading days | +2.6% | 3 of 5 |
| Next 30 trading days | +2.4% | 3 of 5 |
For scale, INCY’s typical 20-trading-day move in either direction is about 5.4%.
Incyte’s market cap is $24.66B, with a P/E ratio of 62.1 and revenue of $6.01B over the last twelve months.
Coverage of Incyte this week reads positive: 9 positive, 9 neutral and 1 negative headlines.
Incyte’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Incyte’s market cap is $24.66B at the Nov 13, 2026 close of $120.97, with 203.8M shares outstanding. The shares trade on a P/E ratio of 62.1.
The consensus analyst 12-month price target for Incyte is $131.50, +8.7% from the last close. Of the 21 firms that rated the stock in the last 90 days, 10 rate it a buy, 11 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Incyte is about fair value: the Nov 13, 2026 close of $120.97 is 1.7% above Gekko Fair Value of $118.98. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Incyte is expected to report on Feb 9, 2027, before the market opens (86 days away). Analysts expect earnings of $1.90 per share on revenue of $1.56B. Incyte beat the earnings estimate in 5 of its last 8 reports, moving 7.7% on average across the report.
Incyte’s 52-week high is $132.60 and its 52-week low is $89.25; it closed at $120.97 on Nov 13, 2026, +11.7% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, smart money, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.